Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: An analysis of the European Group for Blood and Marrow Transplantation registry

Journal of Clinical Oncology

Volumn 29, Issue 10, 2011, Pages 1342-1348

  Van Kampen, Roel J W ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Canals, Carmen ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Schouten, Harry C ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Nagler, Arnon ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Thomson, Kirsty J ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Vernant, Jean Paul ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Buzyn, Agnes ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Boogaerts, Marc A ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Luan, Jian Jian ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Maury, Sebastien ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Milpied, Noel J ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Jouet, Jean Pierre ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Ossenkoppele, Gert J ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Sureda, Anna ^{a,b,c,d,e,f,g,h,i,j,k,l,m}  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c European EBMT Data Office   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

ⁱ MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^j VU UNIVERSITY AMSTERDAM   (Netherlands)

^k SHEBA MEDICAL CENTER   (Israel)

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

^m UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN A; LYMPHOCYTE ANTIBODY; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVOR; CARDIOTOXICITY; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DATA BASE; FEMALE; HLA MATCHING; HUMAN; IMPLANT REGISTRY; INFECTION; INTERSTITIAL PNEUMONIA; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NONRELAPSE MORTALITY; ORGAN DONOR; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; SALVAGE THERAPY; SIBLING; TOXICITY; VEIN OCCLUSION;

EID: 79954441806     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.2596     Document Type: Article

References (37)

1. Philip T, Armitage JO, Spitzer G, et al: High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 316:1493-1498, 1987 (Pubitemid 17076232)
2. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
3. Armitage JO: How I treat patients with diffuse large B-cell lymphoma. Blood 110:29-36, 2007 (Pubitemid 47026815)
4. Seshadri T, Kuruvilla J, Crump M, et al: Salvage therapy for relapsed/refractory diffuse large B cell lymphoma. Biol Blood Marrow Transplant 14:259-267, 2008 (Pubitemid 351218193)
5. Atkins CD: Autologous bone marrow transplantation in relapsed non-Hodgkin's lymphoma. N Engl J Med 334:990, 1996
6. Vose JM, Bierman PJ, Anderson JR, et al: Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: Clinical course and patient follow-up. Blood 80:2142-2148, 1992
7. Bishop MR, Dean RM, Steinberg SM, et al: Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol 19:1935-1940, 2008
8. Doocey RT, Toze CL, Connors JM, et al: Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 131:223-230, 2005 (Pubitemid 43899690)
9. Dann EJ, Daugherty CK, Larson RA: Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma. Bone Marrow Transplant 20:369-374, 1997 (Pubitemid 27390409)
10. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al: An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: Allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 31:667-678, 2003 (Pubitemid 36553477)
11. Schouten HC, Armitage JO, Klassen LW, et al: Allogeneic bone marrow transplantation in patients with lymphoma relapsing after autologous marrow transplantation. Bone Marrow Transplant 4:119-121, 1989 (Pubitemid 19064918)
12. Freytes CO, Loberiza FR, Rizzo JD, et al: Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: A report of the International Bone Marrow Transplant Registry. Blood 104:3797-3803, 2004 (Pubitemid 39564460)
13. Radich JP, Gooley T, Sanders JE, et al: Second allogeneic transplantation after failure of first autologous transplantation. Biol Blood Marrow Transplant 6:272-279, 2000
14. Kim SW, Tanimoto TE, Hirabayashi N, et al: Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: A nationwide survey in Japan. Blood 108:382-389, 2006 (Pubitemid 43990653)
15. van Besien K, Carreras J, Bierman PJ, et al: Unrelated donor hematopoietic cell transplantation for non-Hodgkin lymphoma: Long-term outcomes. Biol Blood Marrow Transplant 15:554-563, 2009
16. Hamadani M, Benson DM Jr, Hofmeister CC, et al: Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant 15:547-553, 2009
17. Nagler A, Slavin S, Varadi G, et al: Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 25:1021-1028, 2000 (Pubitemid 30303589)
18. Morris E, Thomson K, Craddock C, et al: Outcomes after alemtuzumab-containing reducedintensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 104:3865-3871, 2004 (Pubitemid 39620131)
19. Robinson SP, Goldstone AH, Mackinnon S, et al: Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: An analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100:4310-4316, 2002 (Pubitemid 35429668)
20. Escalón MP, Champlin RE, Saliba RM, et al: Nonmyeloablative allogeneic hematopoietic transplantation: A promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 22:2419-2423, 2004 (Pubitemid 41115399)
21. Dean RM, Fowler DH, Wilson WH, et al: Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-Hodgkin lymphoma. Biol Blood Marrow Transplant 11:593-599, 2005 (Pubitemid 41001634)
22. Thomson KJ, Morris EC, Bloor A, et al: Favorable long-term survival after reducedintensity allogeneic transplantation for multiplerelapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 27:426-432, 2009
23. Glass B, Hasenkamp J, Goerlitz A, et al: Allogeneic stem cell transplantation with intermediate conditioning is effective in high risk relapse and progressive disease of aggressive non-Hodgkinlymphoma. Blood (ASH Annual Meeting Abstracts) 114:3379, 2009
24. Rezvani A, Norasetthada L, Sorror M, et al: Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: A multicentre experience. Br J Haemat 143:395-403, 2008
25. Labopin M, Iacobelli S: Statistical Guidelines for EBMT, 2003. http://www.ebmt.org/1WhatisEBMT/Op-Manual/OPMAN-StatGuidelines-oct2003.pdf
26. Przepiorka D, Weisdorf D, Martin P, et al: 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15:825-828, 1995
27. Bierman PJ, Sweetenham JW, Loberiza FR Jr, et al: Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: A comparison with allogeneic and autologous transplantation - The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 21:3744-3753, 2003 (Pubitemid 46606228)
28. Jones RJ, Ambinder RF, Piantadosi S, et al: Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77:649-653, 1991
29. Ratanatharathorn V, Uberti J, Karanes C, et al: Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 84:1050-1055, 1994 (Pubitemid 24245868)
30. Verdonck LF: Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma: Updated results of the Utrecht experience. Leuk Lymphoma 34:129-136, 1999 (Pubitemid 29248667)
31. Schimmer AD, Jamal S, Messner H, et al: Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): Results of a provincial strategy - Ontario BMT Network, Canada. Bone Marrow Transplant 26:859-864, 2000
32. van Besien KW, de Lima M, Giralt SA, et al: Management of lymphoma recurrence after allogeneic transplantation: The relevance of graft-versuslymphoma effect. Bone Marrow Transplant 19:977-982, 1997 (Pubitemid 27232173)
33. Slavin S, Nagler A, Naparstek E, et al: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756-763, 1998 (Pubitemid 28078275)
34. Giralt S, Estey E, Albitar M, et al: Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 89:4531-4536, 1997 (Pubitemid 27260263)
35. Kottaridis PD, Milligan DW, Chopra R, et al: In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96:2419-2425, 2000
36. McSweeney PA, Niederwieser D, Shizuru JA, et al: Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97:3390-3400, 2001
37. Sorror ML, Storer BE, Maloney DG, et al: Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 111:446-452, 2008